The Business Times
business-time-50

AstraZeneca's immunotherapy drug wins key lung cancer approval

Published Sun, Feb 18, 2018 · 09:50 PM

    London

    ASTRAZENECA'S immunotherapy drug Imfinzi has won crucial approval from US regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.

    The US Food and Drug Administration said late on Friday that it granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients with inoperable mid-stage disease that has not spread widely around the body.

    AstraZeneca

    TRENDING NOW

    Asian investors continue to allocate capital to global markets, while maintaining significant exposure to US assets. 

    Despite the de-dollarisation debate, demand for dollar liquidity in Asia is growing

    From left: Pham Nhat Quan Anh, Pham Nhat Vuong, Pham Thu Huong and Pham Nhat Minh Hoang. The couple (centre) remain senior figures in Vingroup, with their children’s presence in the ecosystem growing.

    He built the Vingroup empire. Now South-east Asia’s richest man is handing some key roles to his sons

    The 46,106 sq ft site in Lorong Puntong/Sin Ming Avenue can generate about 140 private housing units.

    Malaysian developer Eco World tops bids for Sin Ming area housing plot with S$1,612 psf ppr offer

    Industry observers broadly see China as bringing its taxation of offshore trusts closer to mature tax regimes in the West.

    As China trust-tax deadline looms, wealthy clients explore options across Asia

    Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
    Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
    View More